Azapeptide activity-based probes for the SARS-CoV-2 main protease enable visualization of inhibition in infected cells.

ABSTRACT: The COVID-19 pandemic has revealed the vulnerability of the modern, global society. With expected waves of future infections by SARS-CoV-2, treatment options for infected individuals will be crucial in order to decrease mortality and hospitalizations. The SARS-CoV-2 main protease is a validated drug target, for which the first inhibitor has been approved for use in patients. To facilitate future work on this drug target, we designed a solid-phase synthesis route towards azapeptide activity-based probes that are capped with a cysteine-reactive electrophile for covalent modification of the active site of M^pro. This design led to the most potent ABP for M^pro and one of the most potent inhibitors reported thus far. We demonstrate that this ABP can be used to visualize M^pro activity and target engagement by drugs in infected cells.

SUBMITTER: Vanhoutte R 

PROVIDER: S-EPMC9931053 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature